AMRN:NSD-Amarin Corporation PLC (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.20

Change

+0.03 (+2.56)%

Market Cap

USD 0.47B

Volume

4.55M

Avg Analyst Target

USD 2.00 (+66.67%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AMRN Stock Forecast & Price:
Based on the Amarin Corporation PLC stock forecasts from 1 analysts, the average analyst target price for Amarin Corporation PLC is USD 2.00 over the next 12 months. Amarin Corporation PLC’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Amarin Corporation PLC is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Amarin Corporation PLC’s stock price was USD 1.20. Amarin Corporation PLC’s stock price has changed by +0.84% over the past week, -6.98% over the past month and -66.76% over the last year.

About Amarin Corporation PLC (AMRN:NSD)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescriptio ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+1.15 (+0.15%)

USD81.40B 15.14 12.35
VRTX Vertex Pharmaceuticals Inc

+3.74 (+1.18%)

USD80.04B 24.25 17.39
MRNA Moderna Inc

+5.70 (+3.18%)

USD67.59B 6.10 4.60
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+9.18 (+5.64%)

USD39.94B 3.92 1.87
GMAB Genmab AS

+0.12 (+0.26%)

USD29.93B 36.52 3.71
ALNY Alnylam Pharmaceuticals Inc

+6.68 (+2.89%)

USD28.46B N/A -29.83
SGEN Seagen Inc

+5.88 (+4.93%)

USD22.16B 55.02 -38.32
ARGX argenx NV ADR

+5.15 (+1.34%)

USD21.93B N/A -22.20
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AMRN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -64.39% 41% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.39% 41% F 25% F
Trailing 12 Months  
Capital Gain -64.18% 45% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.18% 45% F 26% F
Trailing 5 Years  
Capital Gain -63.08% 51% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.08% 51% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain 57.18% 90% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.18% 90% A- 93% A
Risk Return Profile  
Volatility (Standard Deviation) 205.37% 7% F 5% F
Risk Adjusted Return 27.84% 81% B- 68% D+
Market Capitalization 0.47B 73% C 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 73.50 10% F 14% F
Price/Book Ratio 0.84 73% C 80% B-
Price / Cash Flow Ratio -7.10 73% C 68% D+
EV/EBITDA -2.60 68% D+ 68% D+
Management Effectiveness  
Return on Equity -14.95% 90% A- 47% F
Return on Invested Capital 1.07% 86% B 61% D-
Return on Assets -3.14% 94% A 45% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.44 55% F 41% F
Short Percent 4.76% 40% F 31% F
Beta 1.78 17% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.